Research programme: Fc receptor modulators - InKine Pharmaceuticals

Drug Profile

Research programme: Fc receptor modulators - InKine Pharmaceuticals

Alternative Names: CBP 2011 series - InKine

Latest Information Update: 20 Jul 2009

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator InKine Pharmaceutical
  • Class
  • Mechanism of Action Fc receptor modulators; Progesterone receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Autoimmune haemolytic anaemia; Rheumatoid arthritis; Systemic lupus erythematosus

Most Recent Events

  • 03 Oct 2005 InKine Pharmaceutical has been acquired by Salix Pharmaceuticals
  • 20 May 2003 Preclinical trials in Autoimmune haemolytic anaemia in USA (unspecified route)
  • 20 May 2003 Preclinical trials in Rheumatoid arthritis in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top